Healthcare Industry News: AGA Medical
News Release - November 2, 2009
AGA Medical Wins Injunction Against Occlutech's Figulla FlexMINNEAPOLIS, Nov., 2--(HSMN NewsFeed)--AGA Medical Holdings, Inc. (AGA Medical) (NASDAQ:AGAM ) today announced that the German Regional Court in Düsseldorf, Germany has granted a preliminary injunction against the manufacture, possession and sale of the Figulla® Flex occluders manufactured by Occlutech GmbH in Jena, Germany. The judge determined that the Figulla® Flex occluders infringe AGA Medical’s patent EP 0 808 138 in Germany. On October 29, a bailiff was sent to Occlutech’s facility in Jena and seized over 2,700 infringing devices.
As a result of this decision and the prior decisions of the German courts, Occlutech GmbH is now prevented from selling any of its occlusion products in Germany or producing them for sale outside of Germany. The injunction was granted soon after the German Federal Patent Court in Munich upheld the validity of AGA Medical’s patent. Although these decisions are subject to appeal, they continue to be enforced in Germany.
About AGA Medical Corporation
AGA Medical Corporation, based in Plymouth, Minn., is a leader in developing interventional devices for the minimally invasive treatment of structural heart defects and peripheral vascular disorders. Founded in 1995 by Dr. Kurt Amplatz, a former University of Minnesota professor and researcher, AGA Medical’s range of AMPLATZER® products help improve patient outcomes, reduce length of hospital stay and accelerate patient recovery times. AMPLATZER products significantly advanced the treatment of the most common congenital “holes in the heart,” such as atrial septal defects, patent foramen ovale and ventricular septal defects. More than 1,500 articles supporting the benefits of AMPLATZER products have been published in medical literature. AGA Medical Holdings markets AMPLATZER products in 112 countries worldwide. For more information, visit www.amplatzer.com.
Source: AGA Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.